BASTIDE LE CONFORT MEDICAL (BLC.PA) Stock Fundamental Analysis
Europe - EPA:BLC - FR0000035370 - Common Stock
24 EUR
0 (0%)
Taking everything into account, BLC scores 4 out of 10 in our fundamental rating. BLC was compared to 31 industry peers in the Health Care Providers & Services industry. While BLC is still in line with the averages on profitability rating, there are concerns on its financial health. BLC has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year BLC was profitable.
In the past year BLC had a positive cash flow from operations.
Of the past 5 years BLC 4 years were profitable.
In the past 5 years BLC always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of BLC (0.25%) is worse than 80.65% of its industry peers.
The Return On Equity of BLC (2.25%) is worse than 77.42% of its industry peers.
BLC's Return On Invested Capital of 5.65% is in line compared to the rest of the industry. BLC outperforms 54.84% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BLC is in line with the industry average of 6.26%.
The last Return On Invested Capital (5.65%) for BLC is above the 3 year average (5.34%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 2.25% | ||
| ROIC | 5.65% |
ROA(3y)1.29%
ROA(5y)1.7%
ROE(3y)9.6%
ROE(5y)12.13%
ROIC(3y)5.34%
ROIC(5y)5.17%
1.3 Margins
With a Profit Margin value of 0.32%, BLC is not doing good in the industry: 77.42% of the companies in the same industry are doing better.
BLC has a Operating Margin of 7.67%. This is in the better half of the industry: BLC outperforms 64.52% of its industry peers.
In the last couple of years the Operating Margin of BLC has grown nicely.
Looking at the Gross Margin, with a value of 67.54%, BLC is in the better half of the industry, outperforming 77.42% of the companies in the same industry.
In the last couple of years the Gross Margin of BLC has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.67% | ||
| PM (TTM) | 0.32% | ||
| GM | 67.54% |
OM growth 3Y3.59%
OM growth 5Y6.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.18%
GM growth 5Y6.9%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BLC is creating some value.
Compared to 1 year ago, BLC has less shares outstanding
BLC has more shares outstanding than it did 5 years ago.
BLC has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.38, we must say that BLC is in the distress zone and has some risk of bankruptcy.
BLC has a worse Altman-Z score (1.38) than 61.29% of its industry peers.
BLC has a debt to FCF ratio of 9.33. This is a negative value and a sign of low solvency as BLC would need 9.33 years to pay back of all of its debts.
The Debt to FCF ratio of BLC (9.33) is comparable to the rest of the industry.
BLC has a Debt/Equity ratio of 5.20. This is a high value indicating a heavy dependency on external financing.
BLC has a Debt to Equity ratio of 5.20. This is amonst the worse of the industry: BLC underperforms 90.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.2 | ||
| Debt/FCF | 9.33 | ||
| Altman-Z | 1.38 |
ROIC/WACC1.19
WACC4.73%
2.3 Liquidity
BLC has a Current Ratio of 1.19. This is a normal value and indicates that BLC is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Current ratio value of 1.19, BLC is doing good in the industry, outperforming 64.52% of the companies in the same industry.
BLC has a Quick Ratio of 1.19. This is a bad value and indicates that BLC is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.96, BLC is in line with its industry, outperforming 54.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.19 | ||
| Quick Ratio | 0.96 |
3. Growth
3.1 Past
The earnings per share for BLC have decreased strongly by -71.43% in the last year.
BLC shows a small growth in Revenue. In the last year, the Revenue has grown by 3.24%.
Measured over the past years, BLC shows a quite strong growth in Revenue. The Revenue has been growing by 9.55% on average per year.
EPS 1Y (TTM)-71.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130.77%
Revenue 1Y (TTM)3.24%
Revenue growth 3Y6.06%
Revenue growth 5Y9.55%
Sales Q2Q%3.96%
3.2 Future
Based on estimates for the next years, BLC will show a decrease in Earnings Per Share. The EPS will decrease by -3.34% on average per year.
The Revenue is expected to grow by 5.06% on average over the next years.
EPS Next Y-19.38%
EPS Next 2Y0%
EPS Next 3Y-3.34%
EPS Next 5YN/A
Revenue Next Year-7.71%
Revenue Next 2Y-3.05%
Revenue Next 3Y-0.19%
Revenue Next 5Y5.06%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 109.09, the valuation of BLC can be described as expensive.
77.42% of the companies in the same industry are cheaper than BLC, based on the Price/Earnings ratio.
BLC is valuated expensively when we compare the Price/Earnings ratio to 27.77, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 9.21, which indicates a very decent valuation of BLC.
BLC's Price/Forward Earnings ratio is rather cheap when compared to the industry. BLC is cheaper than 87.10% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.23. BLC is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 109.09 | ||
| Fwd PE | 9.21 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BLC is valued cheaply inside the industry as 83.87% of the companies are valued more expensively.
83.87% of the companies in the same industry are more expensive than BLC, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.92 | ||
| EV/EBITDA | 5.63 |
4.3 Compensation for Growth
A cheap valuation may be justified as BLC's earnings are expected to decrease with -3.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0%
EPS Next 3Y-3.34%
5. Dividend
5.1 Amount
No dividends for BLC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:BLC (10/22/2025, 5:07:45 PM)
24
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.14%
Inst Owner ChangeN/A
Ins Owners1.58%
Ins Owner ChangeN/A
Market Cap176.88M
Revenue(TTM)540.26M
Net Income(TTM)1.71M
Analysts83.33
Price Target36.72 (53%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.22
Dividend Growth(5Y)-3.5%
DP42.86%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)9.09%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-15.27%
EPS NY rev (3m)-26.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 109.09 | ||
| Fwd PE | 9.21 | ||
| P/S | 0.33 | ||
| P/FCF | 3.92 | ||
| P/OCF | 1.58 | ||
| P/B | 2.32 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.63 |
EPS(TTM)0.22
EY0.92%
EPS(NY)2.61
Fwd EY10.86%
FCF(TTM)6.12
FCFY25.49%
OCF(TTM)15.22
OCFY63.4%
SpS73.31
BVpS10.32
TBVpS-19.15
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.15
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 2.25% | ||
| ROCE | 8.61% | ||
| ROIC | 5.65% | ||
| ROICexc | 5.65% | ||
| ROICexgc | 10.3% | ||
| OM | 7.67% | ||
| PM (TTM) | 0.32% | ||
| GM | 67.54% | ||
| FCFM | 8.35% |
ROA(3y)1.29%
ROA(5y)1.7%
ROE(3y)9.6%
ROE(5y)12.13%
ROIC(3y)5.34%
ROIC(5y)5.17%
ROICexc(3y)5.7%
ROICexc(5y)5.58%
ROICexgc(3y)12.68%
ROICexgc(5y)11.8%
ROCE(3y)8.16%
ROCE(5y)7.93%
ROICexgc growth 3Y11.16%
ROICexgc growth 5Y1.85%
ROICexc growth 3Y8.09%
ROICexc growth 5Y5.81%
OM growth 3Y3.59%
OM growth 5Y6.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y12.18%
GM growth 5Y6.9%
F-Score6
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.2 | ||
| Debt/FCF | 9.33 | ||
| Debt/EBITDA | 3.72 | ||
| Cap/Depr | 103.59% | ||
| Cap/Sales | 12.41% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 105.61% | ||
| Profit Quality | 2640.05% | ||
| Current Ratio | 1.19 | ||
| Quick Ratio | 0.96 | ||
| Altman-Z | 1.38 |
F-Score6
WACC4.73%
ROIC/WACC1.19
Cap/Depr(3y)89.47%
Cap/Depr(5y)88.81%
Cap/Sales(3y)10.8%
Cap/Sales(5y)10.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-71.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%130.77%
EPS Next Y-19.38%
EPS Next 2Y0%
EPS Next 3Y-3.34%
EPS Next 5YN/A
Revenue 1Y (TTM)3.24%
Revenue growth 3Y6.06%
Revenue growth 5Y9.55%
Sales Q2Q%3.96%
Revenue Next Year-7.71%
Revenue Next 2Y-3.05%
Revenue Next 3Y-0.19%
Revenue Next 5Y5.06%
EBIT growth 1Y3.82%
EBIT growth 3Y9.86%
EBIT growth 5Y16.32%
EBIT Next Year128.89%
EBIT Next 3Y35.52%
EBIT Next 5YN/A
FCF growth 1Y197.72%
FCF growth 3Y10.22%
FCF growth 5Y6.95%
OCF growth 1Y63.86%
OCF growth 3Y7.62%
OCF growth 5Y8.72%